(Q34680463)

3 August 2017

title

Romosozumab for the treatment of osteoporosis. (English)

1 reference

3 August 2017

0 references

Leonardo Bandeira

1

0 references

John P. Bilezikian

series ordinal

3

object named as

John P Bilezikian

1 reference

3 August 2017

E Michael Lewiecki

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

9 January 2017

1 reference

Expert Opinion on Biological Therapy

3 August 2017

published in

1 reference

3 August 2017

volume

17

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

255-263

1 reference

Osteoporosis prevention, diagnosis, and therapy

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Mechanisms of anabolic therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Clinician's Guide to Prevention and Treatment of Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

The use of parathyroid hormone in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Emerging Therapies for Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

New insights into treatment of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

WNT signaling in bone homeostasis and disease: from human mutations to treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Analyses of bone modeling and remodeling using in vitro reconstitution system with two-photon microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Bone modeling and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Biphasic and Dosage-Dependent Regulation of Osteoclastogenesis by β-Catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Sclerostin: Therapeutic Horizons Based Upon Its Actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Bone mineral density in sclerosteosis; affected individuals and gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Romosozumab in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Teriparatide for osteoporosis: importance of the full course

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

SOST is a target gene for PTH in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

A systematic review of hip fracture incidence and probability of fracture worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Incidence of hip fracture in Brazil and the development of a FRAX model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Latitude, socioeconomic prosperity, mobile phones and hip fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

WNT signalling pathways as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Three decades of Wnts: a personal perspective on how a scientific field developed

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280455

10.1080/14712598.2017.1280455

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference